Fesoterodine Fumarate Tablet, Extended Release
Product Images NDC 43598-247

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Fesoterodine Fumarate (NDC 43598-247). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Dr.reddy's Laboratories Inc.,, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Container4mg (Container4mg)

Packaging label for Fesoterodine Fumarate extended-release tablets, 4 mg strength. The label shows the drug name, dosage form, strength, quantity of 30 tablets, and manufacturer Dr. Reddy's Laboratories Inc. The label includes storage instructions, usage notes, and a barcode. The product is marked Rx only and made in India.*

FDA Label Image

Container8mg (Container8mg)

Fesoterodine fumarate 8 mg extended-release tablets label for oral use, produced by Dr. Reddy's Laboratories Inc. The label indicates a package size of 30 tablets and includes storage instructions to keep at 20°C to 25°C (68°F to 77°F). It advises against chewing, dividing, or crushing the tablets. The label shows NDC 43598-248-30 and features a barcode and manufacturing details indicating the product is made in India.*

FDA Label Image

Figure1 (Figure1)

A line graph titled 'Change in Number of Micturitions per 24 h (Study 1)' showing mean change from baseline in number of micturitions over 12 weeks. The x-axis represents time in weeks, and the y-axis shows mean change from baseline. Three lines compare placebo (dotted line), fesoterodine fumarate 4 mg (dashed line with triangles), and fesoterodine fumarate 8 mg (solid line with squares). Both fesoterodine doses show greater reduction in micturitions compared to placebo.*

FDA Label Image

Figure2 (Figure2)

A line graph titled 'Change in Urge Incontinence Episodes per 24 h (Study 1)' showing mean change from baseline in urge incontinence episodes over 12 weeks. It compares placebo, Fesoterodine fumarate 4 mg, and Fesoterodine fumarate 8 mg, with episodes decreasing more significantly for the 8 mg and 4 mg doses than placebo over time.*

FDA Label Image

Figure3 (Figure3)

Line graph depicting change in number of micturitions per 24 hours over 12 weeks from Study 2. The vertical axis shows mean change from baseline in number of micturitions per 24 hours, ranging from 0 to -3, and the horizontal axis shows time in weeks from 0 to 12. Data lines compare placebo to Fesoterodine fumarate 4 mg and 8 mg dosages, with both dosages showing greater reduction in number of micturitions compared to placebo.*

FDA Label Image

Figure4 (Figure4)

A line graph showing the change in number of urge incontinence episodes per 24 hours over 12 weeks. Three treatment groups are compared: Placebo, Fesoterodine fumarate 4 mg, and Fesoterodine fumarate 8 mg. The graph shows mean change from baseline with the 8 mg dose having the greatest reduction, followed by 4 mg, then placebo.*

FDA Label Image

Logo1 (Logo1)

Chemical structure of Fesoterodine fumarate, depicting its molecular arrangement as presented in the image for the prescription drug by Dr.Reddy's Laboratories Inc.*

FDA Label Image

Structure (Structure)

Chemical structure of fesoterodine fumarate, showing its molecular configuration including aromatic rings, ester and amide functional groups, and fumaric acid component.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.